Ventus Therapeutics Revenue and Competitors

Location

#938

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Ventus Therapeutics's estimated annual revenue is currently $17.5M per year.(i)
  • Ventus Therapeutics's estimated revenue per employee is $155,000
  • Ventus Therapeutics's total funding is $300M.

Employee Data

  • Ventus Therapeutics has 113 Employees.(i)
  • Ventus Therapeutics grew their employee count by 11% last year.

Ventus Therapeutics's People

NameTitleEmail/Phone
1
Head Clinical OperationsReveal Email/Phone
2
Head Human ResourcesReveal Email/Phone
3
VP, Head drug discovery - Montréal site headReveal Email/Phone
4
Head Protein SciencesReveal Email/Phone
5
VP, Intellectual Property and LegalReveal Email/Phone
6
Head Platform TechnologiesReveal Email/Phone
7
SVP Preclinical Development, Regulatory and ComplianceReveal Email/Phone
8
VP FinanceReveal Email/Phone
9
Head HRReveal Email/Phone
10
VP Intellectual Property and LegalReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$25.9M1813%$150.5MN/A
#2
$28.4M183-56%N/AN/A
#3
$4.3M288%N/AN/A
#4
$55.6M3591%N/AN/A
#5
$11M7120%N/AN/A
#6
$22.2M143-22%N/AN/A
#7
$4.2M2713%N/AN/A
#8
$2M130%N/AN/A
#9
$295.7M19085%N/AN/A
#10
$2.8M186%N/AN/A
Add Company

What Is Ventus Therapeutics?

Ventus is a newly established venture-backed biotech company pursuing small molecule therapeutics targeting key innate immune pathways for numerous auto-immune and auto-inflammatory diseases. Ventus was founded by world leaders in structural immunology and innate immunity who discovered that innate immune signaling leads to the formation of multimeric complexes that drive the subsequent inflammatory cascade. Leveraging the expertise of our founders, Ventus is the only company capable of pursuing biochemical and structure-based drug discovery for highly sought-after targets of these multimeric complexes.

keywords:N/A

$300M

Total Funding

113

Number of Employees

$17.5M

Revenue (est)

11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Ventus Therapeutics News

2022-03-30 - CFOs On the Move: Week Ending April 1

Boeing Global Services, Express, Sierra Space, OppFi, Lumen Technologies, CKE Restaurants, Milestone, M2GEN, Ventus Therapeutics, AnyRoad.

2022-03-30 - Ventus Therapeutics Appoints Christine Ha as Chief Financial ...

Ventus Therapeutics is a biopharmaceutical company utilizing structural biology and computational tools to identify and develop small molecule...

2021-04-08 - Ventus Therapeutics Closes $100 Million Series B Financing

Ventus Therapeutics, Inc., a biotechnology company utilizing rational structure-based drug design to discover small-molecule medicines for high value and elusive targets, today announced a $100 million Series B financing led by RA Capital Management with participation from a select syndicate inc ...

2021-04-08 - Ventus Therapeutics Raises $100M in Series B Financing

Ventus Therapeutics, Inc., a Boston, Massachusetts and Montreal, Canada-based biotechnology company utilizing rational structure-based drug design to discover small-molecule medicines for high value and elusive targets, raised $100m in Series B financing. The round was led by RA Capital Managem ...

2020-05-06 - Ventus Therapeutics Launches with $60 Million Series A

WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics Inc. today announced a $60 million Series A financing led by founding investor Versant Ventures with participation by GV (formerly Google Ventures). Proceeds will be used to advance three pipeline programs and to expand the company’ ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$16.4M1132%N/A
#2
$23.2M113-10%N/A
#3
$15.8M11355%N/A
#4
$16.4M113-16%N/A
#5
$16.4M1132%N/A